Acne News and Research

Latest Acne News and Research

Top-line results from Cipher's CIP-ISOTRETINOIN Phase III study against severe nodular acne

Cipher Pharmaceuticals Inc. today provided top-line safety and efficacy results from the Phase III safety study of CIP-ISOTRETINOIN, the Company's novel, patented formulation of isotretinoin for the treatment of severe, nodular acne.

8 Jun 2011

Leukemia, psoriasis drugs may treat vascular diseases

A drug that has been on the market for decades to treat leukemia and skin disorders such as acne and psoriasis may be a possible therapy for vascular diseases, including atherosclerosis and hypertension, which can lead to heart attack or stroke.

27 May 2011

Invida announces launch of novel atopic dermatitis symptomatic treatment

Invida Group Private Limited reaffirmed its commitment to patients in Asia Pacific by announcing the launch of a novel atopic dermatitis symptomatic treatment, Atopiclair, which will be available to patients across Asia in second half of 2011.

26 May 2011

Scientific evidence supports benefits of sunscreen usage to prevent skin cancer

The American Academy of Dermatology today reiterated the safety and effectiveness of sunscreens to protect against the damaging effects from exposure to ultraviolet (UV) radiation. As one component of a daily sun-protection strategy, sunscreen is an important tool in the fight against skin cancer, including melanoma, the deadliest form of skin cancer.

24 May 2011

XTRAC Excimer Laser treatment offers new hope for patients with psoriasis

With XTRAC® Excimer Laser treatments, psoriasis patients can say goodbye to the red, dry patches of scaly, thickened skin they have been covering up all winter. Developed by PhotoMedex, Inc., an innovator of medical devices, the XTRAC laser offers new hope to the 7.5 million Americans suffering from this embarrassing and socially isolating disease.

19 May 2011

$Alma Lasers launches new iPixel series aesthetic fractional laser resurfacing modules$

Alma Lasers launches new iPixel series aesthetic fractional laser resurfacing modules

Alma Lasers Ltd., a global leader in laser, light, radiofrequency and ultrasound-based aesthetic treatment devices, today announced the launch of its new iPixel series of innovative pixel modules for aesthetic fractional laser resurfacing.

12 May 2011

Cipher first quarter net revenue decreases to $0.7 million

Cipher Pharmaceuticals Inc. today announced its financial and operational results for the three months ended March 31, 2011.

12 May 2011

GSK, NanoBio initiate two NB-001 Phase 3 trials in cold sores

NanoBio Corporation today announced the initiation of two Phase 3 multicenter trials evaluating NB-001 as a topical treatment for cold sores, a step forward in their OTC licensing agreement with GlaxoSmithKline Consumer Healthcare.

12 May 2011

Helix BioMedix total revenue increases 413% to $358,000 for first quarter 2011

Helix BioMedix, Inc., a developer of bioactive peptides, today announced financial results for the company's first quarter ended March 31, 2011.

7 May 2011

FDA clears Solta Medical's new Clear + Brilliant laser aesthetic skin treatment

Solta Medical, Inc., the pioneer in fractional resurfacing and non-invasive skin tightening and a global market leader in aesthetic skin treatments today announced it has received FDA 510(k) clearance of its new Clear + Brilliant laser aesthetic treatment, which will officially launch at the World Congress of Dermatology in Seoul, Korea on May 25, 2011.

6 May 2011

PhotoMedex introduces DNA Damage Control sunscreens

PhotoMedex, Inc. a leading supplier of advanced, clinical skincare and medical laser products, today introduced DNA Damage Control, the breakthrough treatment sunscreens that feature advanced photoprotection with DNA repair technology.

5 May 2011

Anacor first quarter revenues increase to $2.2 million

Anacor Pharmaceuticals reviewed today its first quarter accomplishments and reported financial results for the quarter ended March 31, 2011.

5 May 2011

Watson launches Generess Fe low-dose oral contraceptives in the U.S.

Watson Pharmaceuticals, Inc., today announced the U.S. commercial launch of Generess Fe 0.8 mg/25 mcg, a new low-dose oral contraceptive option that's highly effective at preventing pregnancy and proven to provide users with short, lighter, predictable periods.

2 May 2011

Women with PCOS show high levels of blood markers linked with cardiovascular disease

A new study presented at the European Congress of Endocrinology shows that women with polycystic ovary syndrome show higher levels of blood markers associated with cardiovascular disease than control groups.

2 May 2011

FDA approves Abbott's AndroGel for hypogonadism treatment in men

Abbott announced today that the U.S. Food and Drug Administration has approved AndroGel 1.62%, a clear, odorless, gel formulation shown to restore testosterone levels in hypogonadal men with half the volume of gel at the starting dose compared to AndroGel 1%.

30 Apr 2011

AstraZeneca announces U.S. availability of vandetanib for rare medullary thyroid cancer

AstraZeneca today announced that the orphan drug vandetanib is now available to U.S. patients for the treatment of medullary thyroid cancer that cannot be removed by surgery or that has spread to other parts of the body.

25 Apr 2011

Bayer's oral contraceptives may increase risk of blood clots, stroke or heart attack

Bayer HealthCare Pharmaceuticals, Inc. is aware of two studies published today in The British Medical Journal, ONLINE FIRST.

25 Apr 2011

Avita's ReCell Spray-On Skin exhibits potential for applications relating to healing of acute wounds

Avita Medical Ltd., the regenerative medicine company, announced today that a clinical study of 18 patients suffering from partial-thickness burns, some of which had failed to heal after treatment with other wound-healing methods ('chronic wounds'), demonstrated successful wound-healing after being treated with ReCell® Spray-On Skin™ from Avita Medical.

22 Apr 2011

State Roundup: Mass. considers new health payment system

The California Public Employees' Retirement System is negotiating a lucrative pharmacy benefits management contract with Caremark Rx Inc., a company being sued for defrauding the pension fund of tens of millions of dollars (Lifsher, 4/16).

18 Apr 2011

AstraZeneca's vandetanib receives FDA approval in medullary thyroid cancer

AstraZeneca today announced that the U.S. Food and Drug Administration approved the orphan drug vandetanib for the treatment of medullary thyroid cancer that cannot be removed by surgery or that has spread to other parts of the body.

7 Apr 2011